

Corinne Haioun

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7226639/corinne-haioun-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

10
papers

712
citations

9
h-index

11
g-index

11
ext. papers

972
ext. citations

6.1
avg, IF

2.75
L-index

#	Paper	IF	Citations
10	Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma. <i>Blood Advances</i> , 2021 , 5, 539-548	7.8	6
9	Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma. <i>Blood</i> , 2018 , 132, 2305-2309	2.2	68
8	Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study. <i>Lancet Haematology</i> , 2018 , 5, e403-e410	14.6	17
7	Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin. <i>Haematologica</i> , 2017 , 102, e148-e151	6.6	89
6	Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2008-2017	2.2	98
5	Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas. <i>Blood</i> , 2016 , 128, 1490-502	2.2	170
4	The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 15084-15089	11.5	58
3	Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets. <i>Haematologica</i> , 2015 , 100, e361-4	6.6	60
2	A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. <i>European Journal of Cancer</i> , 2013 , 49, 2869-76	7.5	88
1	Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA. <i>Haematologica</i> , 2012 , 97, 1594-602	6.6	58